Medicago signs MOU with NITT Partners for commercial development of influenza vaccines in Japan

	    QUEBEC CITY, March 16 /CNW/ - Medicago Inc. (TSX-V: MDG), a biotechnology
company focused on developing highly effective and affordable vaccines based
on proprietary manufacturing technologies and Virus-Like Particles (VLPs),
today announced that it has signed a Memorandum of Understanding ("MOU") with
Niigata TLO/NBRP/KUTLO-NITT ("NITT Partners") to discuss and negotiate an
agreement to commercialize Medicago's pandemic and seasonal influenza
VLP-based vaccines in Japan and other territories. For several years, NITT
Partners has been the government approved technology transfer/licensing
organization to license in state of the art technologies. Under the terms of
the MOU, the parties will evaluate and select an optimal deal structure with
the objective of formalizing a definitive agreement.
	    "We are delighted to be collaborating with NITT Partners to potentially
enable funding to support the development of our VLP-based influenza vaccines
in Japan," Andy Sheldon, President and CEO of Medicago. "This further
validates our unique plant-based vaccine technology offering of a rapid,
affordable and effective solution for the supply of vaccines within country
borders."
	    "The successful completion of our Phase I clinical trial for our H5N1
vaccine candidate has opened additional global doors and has also advanced the
ongoing discussions with our potential partners," said Frederic Ors, VP
Business Development of Medicago. "As we advance the clinical development of
our vaccine candidates, we will continue to discuss opportunities with other
pharmaceutical companies and governments to roll-out our compelling influenza
vaccine technology around the globe."
	    "Medicago's VLP technology coupled with their portable manufacturing
system has the potential to allow Japan to manufacture vaccines within our
borders," said Yoji YUKI, President and CEO of Niigata TLO. "The speed,
capacity and cost of vaccine production have the potential to be drastically
improved as Medicago's plant-based technology has proven to develop emerging
strains quicker and at a less expensive rate. As we enter a new world of high
technology, we are confident that Medicago's technology has the ability to
help conquer the spread of influenza virus, further enhancing our pandemic
plan."

	    About NITT Partners

	    NITT Partners are the managing members of the Consortium "KUTLO-NITT"
which is the government approved universities technology transfer/licensing
organization whose role is to license out bio & life science technologies
developed by eleven member universities in Japan, and license in state of the
art technologies to Japan. KUTLO-NITT met Medicago for the first time in May
2009 at an international convention, "BIO2009" at Atlanta, Georgia, U.S.A.,
where a successful connection was made with their influenza vaccine
specialists.

	    About Medicago

	    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

	    Forward Looking Statements

	    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

	    Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release






-30-

	    /For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Medicago Inc., Christina Cameron, Investor Relations
Manager, (647) 962-9393/